First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose.
Drugs and pharma giants Pfizer...
Omicron has a substantial growth advantage over the Delta strain of COVID-19 and is rapidly replacing Delta globally, particularly because it is able to...
Relying solely on the Chinese-manufactured Sinovac inactive vaccine is not enough to reduce transmission rates of COVID-19. Millions of people in 48 countries around...
The UN appeal comes at a moment when humanitarian funding is already stretched by multiple crises. While CERF has provided rapid support, broader donor commitments remain insufficient relative to the scale of projected need.
South Asia’s lead crisis is not inevitable. Experience elsewhere demonstrates that decisive regulation, industrial formalisation and community-level interventions can sharply reduce exposure.
The UN appeal comes at a moment when humanitarian funding is already stretched by multiple crises. While CERF has provided rapid support, broader donor commitments remain insufficient relative to the scale of projected need.